Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 14, 2014, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $39.62 to $83,032,124.16.

Highlighted Stocks Traded by Insiders:

Manhattan Associates (MANH) - FREE Research Report

Huntz John J Jr who is Director at Manhattan Associates sold 14,156 shares at $39.33 on March 14, 2014. Following this transaction, the Director owned 67,956 shares meaning that the stake was reduced by 17.24% with the 14,156-share transaction.

The shares most recently traded at $39.35, up $0.02, or 0.05% since the insider transaction. Historical insider transactions for Manhattan Associates go as follows:

  • 4-Week # shares sold: 1,677
  • 12-Week # shares sold: 68,968
  • 24-Week # shares sold: 73,061

The average volume for Manhattan Associates has been 542,600 shares per day over the past 30 days. Manhattan Associates has a market cap of $3.0 billion and is part of the technology sector and computer software & services industry. Shares are up 32.72% year-to-date as of the close of trading on Friday.

Manhattan Associates, Inc. develops, sells, deploys, services, and maintains supply chain commerce software solutions for retailers, wholesalers, manufacturers, governments, and other organizations to enhance their supply chain operations from planning through execution. The company has a P/E ratio of 45.3. Currently there are 2 analysts that rate Manhattan Associates a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MANH - FREE

TheStreet Quant Ratings rates Manhattan Associates as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Manhattan Associates Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cheniere Energy (LNG) - FREE Research Report

Brandolini Nuno who is Director at Cheniere Energy sold 2,000 shares at $49.32 on March 14, 2014. Following this transaction, the Director owned 10,000 shares meaning that the stake was reduced by 16.67% with the 2,000-share transaction.

The shares most recently traded at $51.14, up $1.82, or 3.56% since the insider transaction. Historical insider transactions for Cheniere Energy go as follows:

  • 4-Week # shares sold: 127,000
  • 12-Week # shares sold: 569,000
  • 24-Week # shares sold: 1.1 million

The average volume for Cheniere Energy has been 3.6 million shares per day over the past 30 days. Cheniere Energy has a market cap of $12.6 billion and is part of the basic materials sector and energy industry. Shares are up 23.12% year-to-date as of the close of trading on Friday.

Cheniere Energy, Inc., an energy company, is engaged in the liquefied natural gas (LNG) related business. It operates through two segments, LNG Terminal Business, and LNG and Natural Gas Marketing Business. Currently there are 5 analysts that rate Cheniere Energy a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNG - FREE

TheStreet Quant Ratings rates Cheniere Energy as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Cheniere Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acadia Healthcare Company (ACHC) - FREE Research Report

Grieco William who is Director at Acadia Healthcare Company sold 5,000 shares at $46.29 on March 14, 2014. Following this transaction, the Director owned 36,423 shares meaning that the stake was reduced by 12.07% with the 5,000-share transaction.

Fincher Ronald Morgan who is Chief Operating Officer at Acadia Healthcare Company sold 7,785 shares at $46.47 on March 14, 2014. Following this transaction, the Chief Operating Officer owned 123,276 shares meaning that the stake was reduced by 5.94% with the 7,785-share transaction.

The shares most recently traded at $46.95, up $0.48, or 1.02% since the insider transaction. Historical insider transactions for Acadia Healthcare Company go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 82,647
  • 24-Week # shares sold: 182,647

The average volume for Acadia Healthcare Company has been 382,700 shares per day over the past 30 days. Acadia Healthcare Company has a market cap of $2.4 billion and is part of the health care sector and health services industry. Shares are up 0.61% year-to-date as of the close of trading on Friday.

Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, and substance abuse facilities in the United States. The company has a P/E ratio of 55.4. Currently there are 8 analysts that rate Acadia Healthcare Company a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACHC - FREE

TheStreet Quant Ratings rates Acadia Healthcare Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Acadia Healthcare Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null